deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT05590221

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Study to Evaluate the Efficacy and Safety of Relmacabtagene Autoleucel (Relma-cel) as First-Line Therapy in Adult Participants With High-Risk Large B-Cell Lymphoma

Sponsor: Peking University Cancer Hospital & Institute

Conditions B-cell Lymphoma
Interventions Cyclophosphamide Fludarabine Relmacabtagene Autoleucel
Updated 6 times since 2022 Last updated: Jan 5, 2024 Started: Jan 3, 2023 Primary completion: Feb 10, 2024 Completion: Dec 10, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates B-cell Lymphoma and is currently ongoing. Peking University Cancer Hospital & Institute leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2022 – ~Nov 2023 · 12 months · monthly snapshotNot Yet Recruiting~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE2

    Status: Recruiting → Unknown

  2. Sep 2024 — Jan 2026 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Nov 2022 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Peking University Cancer Hospital & Institute
  • Shanghai Ming Ju Biotechnology Co., Ltd.
Data source: Peking University Cancer Hospital & Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations